TD Asset Management Inc Has $8.78 Million Stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

Key Points

• TD Asset Management Inc has reduced its stake in Immunocore Holdings by 6.8%, owning 295,854 shares valued at approximately $8.78 million after selling 21,622 shares in the first quarter.
• Immunocore's recent earnings report showed a profit of $0.10 per share, significantly exceeding expectations, with revenue of $125.13 million, up 33.6% year-over-year.
• Analysts maintain a consensus rating of "Moderate Buy" for Immunocore, with a target price of $58.89, reflecting eight buy ratings against one sell rating.

TD Asset Management Inc lessened its holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 6.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 295,854 shares of the company's stock after selling 21,622 shares during the quarter. TD Asset Management Inc owned 0.59% of Immunocore worth $8,778,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in shares of Immunocore in the fourth quarter worth $25,000. Oppenheimer Asset Management Inc. purchased a new stake in Immunocore during the first quarter valued at about $225,000. Tema Etfs LLC acquired a new stake in Immunocore during the 4th quarter worth approximately $330,000. Virtus ETF Advisers LLC raised its stake in shares of Immunocore by 39.0% in the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock valued at $340,000 after acquiring an additional 3,238 shares during the period. Finally, XTX Topco Ltd raised its position in Immunocore by 22.2% in the fourth quarter. XTX Topco Ltd now owns 18,896 shares of the company's stock valued at $557,000 after purchasing an additional 3,437 shares during the period. Institutional investors and hedge funds own 84.50% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on IMCR shares. Wall Street Zen raised shares of Immunocore from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Oppenheimer raised their target price on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a report on Monday, June 2nd. Mizuho reduced their price target on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Immunocore in a research note on Tuesday, May 27th. They issued a "buy" rating and a $65.00 price target for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $58.89.

Immunocore Stock Performance

Shares of NASDAQ:IMCR traded up $0.05 during trading on Tuesday, reaching $32.58. The stock had a trading volume of 46,420 shares, compared to its average volume of 334,972. Immunocore Holdings PLC Sponsored ADR has a 52 week low of $23.15 and a 52 week high of $39.33. The company has a quick ratio of 6.31, a current ratio of 6.36 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -75.88 and a beta of 0.77. The stock has a fifty day simple moving average of $34.28 and a two-hundred day simple moving average of $31.19.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.45. Immunocore had a negative return on equity of 5.86% and a negative net margin of 6.48%. The firm had revenue of $125.13 million during the quarter, compared to analysts' expectations of $108.82 million. During the same quarter in the prior year, the firm posted ($0.49) EPS. The company's revenue for the quarter was up 33.6% on a year-over-year basis. As a group, analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current fiscal year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.